2. Academic Validation
  3. Revisiting anti-CTLA-4 antibodies in combination with PD-1 blockade for cancer immunotherapy

Revisiting anti-CTLA-4 antibodies in combination with PD-1 blockade for cancer immunotherapy

  • Ann Oncol. 2021 Mar;32(3):295-297. doi: 10.1016/j.annonc.2020.11.018.
M Sznol 1,  I Melero 2
Affiliations

Affiliations

  • 1 Departments of Immunology and Oncology, Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA. Electronic address: [email protected].
  • 2 Department of Immunology, CIMA and Clinica Universidad de Navarra, Pamplona, Spain; CIBERONC, Madrid, Spain.
PMID: 33307201 DOI: 10.1016/j.annonc.2020.11.018
Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-P99809
    ≥99.0%, Monoclonal Antibody